Apyx Medical Corporation

Apyx Medical Corporation is an advanced energy technology company that designs, develops, manufactures, and sells medical devices for both the cosmetic and surgical markets globally. The company's mission is to elevate people's lives through innovative products, delivering transformative energy-based surgical tools aimed at improving patient outcomes, enhancing surgeon efficiency, and reducing healthcare costs. Headquartered in Clearwater, Florida, Apyx Medical was incorporated in 1982 and was formerly known as Bovie Medical Corporation, changing its name in January 2019.

The company's key product offerings are centered around its proprietary helium plasma and radiofrequency technology. These include Renuvion, marketed for the cosmetic surgery market, and J-Plasma, used in the hospital surgical market. Both technologies provide surgeons with the ability to deliver controlled heat to tissue for desired results. Apyx Medical also introduced the AYON Body Contouring System, an all-in-one, surgeon-designed platform that integrates fat removal, closed-loop contouring, electrosurgical capabilities, and Renuvion for tissue contraction. The company also engages in Original Equipment Manufacturing (OEM) agreements, leveraging its expertise in unique waveforms to develop generators and related accessories for other medical device manufacturers.

Under the leadership of President and CEO Charles D. Goodwin, Apyx Medical continues to advance its market position. In May 2024, Stavros Vizirgianakis was appointed Chairman of the Board. The company reported total revenue of $52.8 million for the full year 2025, with a significant portion driven by the commercial launch of the AYON Body Contouring System in September 2025. Apyx Medical's Renuvion technology received the 2026 NewBeauty Award for "Best Minimally Invasive Skin Tightener," marking consecutive recognition for its clinical impact. The company anticipates a 510(k) clearance for AYON power liposuction in mid-2026, further expanding its product capabilities.

Latest updates

Apyx Medical Raises FY2026 Revenue Guidance on Strong Surgical Aesthetics Growth

Event summary

  • Apyx Medical reported $12.5M in Q1 2026 revenue, up 32.4% YoY, driven by 36% growth in Surgical Aesthetics.
  • Raised FY2026 revenue guidance to $59M–$60M from $57.5M–$58.5M, citing strong AYON adoption and international demand.
  • Net loss narrowed to $2.1M from $4.2M YoY, with adjusted EBITDA loss improving to $0.3M from $2.4M.
  • International sales surged 62.9% YoY, with South Korea emerging as a key growth market post-regulatory approval.
  • Renuvion won the 2026 NewBeauty award for 'Best Minimally Invasive Skin Tightener' for the second consecutive year.

The big picture

Apyx Medical's Q1 2026 results reflect a strategic pivot toward Surgical Aesthetics, with AYON and Renuvion driving growth. The company's ability to capitalize on international markets, particularly in Asia, will be key to meeting its upgraded FY2026 guidance. The broader trend of minimally invasive aesthetic procedures gaining traction positions Apyx favorably in a competitive medical devices sector.

What we're watching

International Expansion
Whether Apyx can sustain its 62.9% YoY international growth, particularly in South Korea, where the cosmetic surgery market is projected to exceed $3.9B by 2031.
Product Adoption
The pace at which AYON adoption accelerates in the U.S., given its commercial launch in Q3 2025 and its role in driving Surgical Aesthetics revenue.
Operational Efficiency
How Apyx balances its focus on Surgical Aesthetics with the expected decline in OEM revenue, which is critical for maintaining profitability.

Apyx Medical to Detail Q1 Results Amidst Body Contouring Market Competition

Event summary

  • Apyx Medical Corporation (APYX) will release its Q1 FY2026 financial results on May 7, 2026, before market open.
  • A conference call to discuss the results will be held at 8:00 AM ET on May 7, 2026, with dial-in and webcast options provided.
  • The company's products include Renuvion®, AYON Body Contouring System™, and J-Plasma®.
  • Apyx Medical leverages its waveform technology through OEM agreements with other medical device manufacturers.

The big picture

Apyx Medical operates within a growing surgical aesthetics market, driven by increasing consumer demand for non-invasive cosmetic procedures. The company’s focus on its Helium Plasma Platform Technology and the AYON system positions it to capitalize on this trend, but faces competition from established players and emerging technologies. The upcoming earnings call will provide insight into the effectiveness of their strategies and the overall health of the business.

What we're watching

Market Dynamics
The success of the AYON Body Contouring System will hinge on Apyx Medical's ability to differentiate its offering within a competitive landscape of body contouring technologies.
OEM Strategy
The contribution of revenue from OEM agreements will be a key indicator of Apyx Medical’s ability to leverage its core technology beyond its direct product sales.
Clinical Data
Continued support for Renuvion and J-Plasma through clinical documentation will be crucial for maintaining market share and justifying premium pricing.
CID: 1695